NCT07449234

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

TERMINATEDOBSERVATIONAL

Trial Details

Start: 2026-02-09Est. Completion: 2026-06-29

Enrollment target: 9 participants

Locations

Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic, immune-mediated, systemic disease affecting less than 1% of people with variatio…

Nice, FranceCompleted Jun 11, 2026

Psoriasis

Psoriasis is an inflammatory skin disease with huge negative impact on the quality of life of the patients, and has an o…

Hong Kong, Hong KongCompleted Mar 27, 2026

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.